Video

IPG: Inflammatory Bowel Disease Chaired by Bruce Sands, MD

Author(s):

This edition of HCPLive® State of the Science involves 3 experts discussing different trends in IBD treatments and care.

A trio of clinicians recently came together to present data and expertise on a variety of issues related to inflammatory bowel disease (IBD) treatments.

On June 10, Bruce E. Sands, MD, Chief of the Dr. Henry D. Janowitz Division of Gastroenterology at Mount Sinai Hospital and the Dr. Burrill B. Crohn Professor of Medicine (Gastroenterology), led the HCPLive® State of the Science Event called Institutional Perspectives in Gastroenterology: Inflammatory Bowel Disease.

Joined by Ryan Ungaro, MD, Assistant Professor of Medicine in the Division of Gastroenterology at the Icahn School of Medicine at Mount Sinai and Jean-Frederic Colombel, MD, Director Inflammatory Bowel Disease Center Icahn School of Medicine at Mount Sinai, the trio discussed the following topics:

  • Managing IBD During COVID-19
  • Early Use of Biologics
  • Emerging Therapies: Newer Biologic Therapies
  • Emerging Therapies: The Return of Small Molecules
Related Videos
Caroline Piatek, MD: High HCRU, Patient Concerns Highlight Great Unmet Need in wAIHA
Steven W. Pipe, MD: Supporting Gene Therapy Implementation for Hemophilia
Corinna L. Schultz, MD: Improving Sickle Cell Trait Documentation in Infancy
Sibgha Zaheer, MD: Determining Washout Period With Fitusiran, Emicizumab Transition for Hemophilia
Pavan K. (Tem) Bendapudi, MD: Large-Scale Analyses Elucidate Genetic Risk of Thrombosis
Seema Rani, MD: Examining Sleep Health in Youth With SCD
Daniel Wang: A More Appropriate Ferritin Threshold is Cost-Effective for Iron Deficiency Screening
Kimberly A. Davidow, MD: Elucidating Risk of Autoimmune Disease in Childhood Cancer Survivors
Yehuda Handelsman, MD: Insulin Resistance in Cardiometabolic Disease and DCRM 2.0 | Image Credit: TMIOA
© 2025 MJH Life Sciences

All rights reserved.